Effectiveness Study of the Guardian RT in Type 1 Diabetics
NCT ID: NCT01331343
Last Updated: 2011-04-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
156 participants
INTERVENTIONAL
2004-06-30
2005-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Guardcontrol Trial: Study to Assess if Type 1 Diabetics Can Improve Using the Real-time Values of Guardian RT
NCT00111228
Use of Real-time Continuous Glucose Monitoring System in Patients With Type 1 Diabetes Mellitus
NCT00824148
Sensor and Software Use for Improved Glucose Control in MDI Managed Diabetes
NCT01713348
Long Term CGM Treatment in Patients With Type 1 Diabetes Treated With Insulin Injections
NCT02465411
Smartguard Use in Real Life : a Longitudinal Study in Patients With Type 1 Diabetes
NCT03047486
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Guardian RT Telemetered Glucose Monitoring System
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* HbA1c must be 8.1% or above at study entry
* Intensive Insulin Therapy 3 months prior to study entry
Exclusion Criteria
* Unable to comply with protocol
* Chronic debilitating or psychiatric disturbances
8 Years
59 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medtronic Diabetes
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Medtronic Internationtal Trading Sarl
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Sud Francilien
Corbeil-Essonnes, , France
CH Robert Debre
Paris, , France
Klinik fur Allgemeine Charite
Berlin, , Germany
Schneider Children Centre
Petah Tikva, , Israel
U.O. Medicina Generale
Milan, , Italy
University Children's Hospital
Ljubljana, , Slovenia
Huddinge University Hospital
Huddinge, , Sweden
Royal Bournemouth Hospital
Dorset, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EU007_022004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.